海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02637 海西新药

已收盘 08-12 16:08:06

196.800

-4.000

-1.99%

最高202.800	最低192.600	成交量5.27万
今开202.800	昨收200.800	日振幅5.08%
总市值154.90亿	流通市值154.90亿	总股本7,871万
成交额1,037万	换手率0.07%	流通股本7,871万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新药","latestPrice":196.8,"timestamp":1786522086307,"preClose":200.8,"halted":0,"volume":52650,"delay":0,"changeRate":-0.0199203187250996,"floatShares":78707270,"shares":78707270,"eps":2.966465783092822,"marketStatus":"已收盘","change":-4,"latestTime":"08-12 16:08:06","open":202.8,"high":202.8,"low":192.6,"amount":10370400,"amplitude":0.050797,"askPrice":197.5,"askSize":200,"bidPrice":196.8,"bidSize":3400,"shortable":3,"etf":0,"ttmEps":2.896666588196521,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786584600000},"marketStatusCode":5,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":200.8,"openAndCloseTimeList":[[1786498200000,1786507200000],[1786510800000,1786521600000]],"volumeRatio":0.344706,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02637","defaultTab":"news","newsList":[{"id":"1126530849","title":"海西新药（02637）拟于8月28日召开董事会审议中期业绩及分红事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1126530849","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126530849?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:46","pubTimestamp":1786527969,"startTime":"0","endTime":"0","summary":"海西新药（02637）8月12日在港交所公告称，公司董事会将于2026年8月28日（星期五）召开会议，主要议程包括：一、审议及批准集团截至2026年6月30日止六个月的中期业绩并发布；二、讨论及建议派付中期股息（如有）；三、处理其他相关事项。\n公告显示，董事会目前由九名董事组成，包括五名执行董事康心汕、Feng Yan、Chen Guangming、李俊青及陈廷泽；一名非执行董事许冬；以及三名独立非执行董事王珊珊、蒲美婷和林斌。\n公司执行董事、董事长兼总经理康心汕代表董事会签署了本次公告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146170998","title":"海西新药（02637）发布补充公告　详释更换外聘核数师原因及后续审计安排","url":"https://stock-news.laohu8.com/highlight/detail?id=1146170998","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146170998?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:16","pubTimestamp":1786446985,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司8月11日发布有关建议更换外聘核数师的补充公告，披露具体时间轴、审计师遴选过程及后续审计计划，并重申与原审计师德勤—关黄陈方会计师行不存在任何意见分歧。公司强调，更换外聘核数师乃应对持续出现的外部监管及融资需求而作出的审慎决定，不涉及对德勤审计质量的任何异议。董事会与审核委员会认为，此举符合公司及股东整体利益，可确保2026年度审计工作在中国准则下顺利进行并避免重复审计成本。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657591850","title":"海西新药盘中涨超14% HX9428在美获批启动II期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2657591850","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657591850?lang=zh_cn&edition=full","pubTime":"2026-08-05 10:22","pubTimestamp":1785896520,"startTime":"0","endTime":"0","summary":"模拟交易客户端海西新药早盘一度涨超14%，截至发稿，股价上涨5.42%，现报196.40港元，成交额2128.27万港元。海西新药发布公告，公司自主研发的创新药候选分子HX9428治疗新生血管性年龄相关性黄斑变性的美国临床试验申请已获美国食品药品监督管理局批准，正式启动II期临床试验；同时，公司在中国启动第二项采用阳性对照的II期临床试验，计划入组60例患者。HX9428尚未获批上市，安全性和有效性需进一步验证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-05/doc-inimfmyp5317024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657459963","title":"港股异动 | 海西新药(02637.HK)早盘涨超14% HX9428在美获批启动II期临床 同时在中国启动临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2657459963","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657459963?lang=zh_cn&edition=full","pubTime":"2026-08-05 09:44","pubTimestamp":1785894295,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168351594","title":"海西新药（02637.HK）HX9428获美FDA批准开展II期临床 并在中国启动对照试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1168351594","media":"公告速递","labels":["productRelease","policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168351594?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:16","pubTimestamp":1785834973,"startTime":"0","endTime":"0","summary":"2026年8月4日，福建海西新药创制股份有限公司发布自愿公告称，公司自主研发的创新药候选分子HX9428用于治疗新生血管性年龄相关性黄斑变性的临床试验申请已获美国食品药品监督管理局批准，许可启动一项II期临床试验。\\n\\n截至公告披露日，HX9428尚未获得任何国家或地区药品监管机构的上市批准，其安全性与有效性仍需通过进一步临床研究验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656460539","title":"海西新药(02637)：HX9428治疗新生血管性年龄相关性黄斑变性获美国FDA IND批准启动II期临床试验 同时在中国启动第二项采用阳性对照的II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2656460539","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656460539?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:15","pubTimestamp":1785834956,"startTime":"0","endTime":"0","summary":"此次获批的IND涵盖一项II期临床试验方案，旨在评估HX9428不同口服剂量在美国 nAMD患者中的有效性及安全性。该研究为集团在HX9428既往I 期及II期剂量扩展研究的基础上，进一步启动的一项随机、阳性对照的II期临床研究。本次美国FDAII期临床试验获批、中国标准疗法对照II期临床试验启动，标志着 HX9428全球临床开发进程取得重要进展，为全面验证HX9428在nAMD治疗中的临床价值奠定坚实基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","02637","BK4588","IND","LABU","PSYK","IBBJ","MDTX","BMED","BK4585","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151906205","title":"海西新药：美国FDA批准Hx9428用于治疗新生血管性年龄相关性黄斑变性的临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1151906205","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151906205?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:13","pubTimestamp":1785834789,"startTime":"0","endTime":"0","summary":"海西新药宣布，其研发的Hx9428药物已获得美国食品药品监督管理局（FDA）批准，可开展针对新生血管性年龄相关性黄斑变性（nAMD）的临床试验申请（IND）。这一进展标志着该公司在眼科疾病治疗领域取得重要突破，为后续临床开发奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104460756","title":"海西新药（02637）2026年首场临时股东会通过更换核数师及补选执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1104460756","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104460756?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:57","pubTimestamp":1785833851,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司于2026年8月4日在福建福州召开2026年第一次临时股东大会。会议以一股一票方式对全部两项普通决议案进行表决，具体结果如下：。截至会议当天，公司已发行股份总数为78,707,270股；具备出席并投票权的股份同为78,707,270股。董事会人事方面，王忻琨先生于会议结束后退任董事职务；陈廷澤先生获股东大会选任为执行董事，任期自股东大会结束之日起至第二届董事会任期届满为止。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118532919","title":"海西新药（02637）公布董事会及四大专门委员会最新构成","url":"https://stock-news.laohu8.com/highlight/detail?id=1118532919","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118532919?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:57","pubTimestamp":1785833829,"startTime":"0","endTime":"0","summary":"2026年8月4日，福建海西新药创制股份有限公司发布公告，更新公司董事会及其下设四个专门委员会的人员名单。公告称，新一届董事会及其专门委员会的组成将自公布之日起生效。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656360015","title":"海西新药(02637)：陈廷泽获选任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2656360015","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656360015?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:56","pubTimestamp":1785833782,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药(02637)发布公告，王忻琨先生于临时股东会结束后退任董事会董事。于临时股东会上，陈廷泽先生获选任为执行董事，由临时股东会结束起，直至第二届董事会任期届满之日止。于临时股东会上，股东已批准罢免德勤‧关黄陈方会计师行及委任容诚会计师事务所(特殊普通合伙)为公司2026年度外聘核数师并授权董事会厘定其酬金。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174432853","title":"海西新药（02637）披露2025年报补充资料：57721.9万元重大投资占总资产31.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174432853","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174432853?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:36","pubTimestamp":1785746207,"startTime":"0","endTime":"0","summary":"2026年8月3日，福建海西新药创制股份有限公司刊发《关于截至2025年12月31日止年度年度报告之补充公告》，就其2025年报的重大投资、关联方关系及物业估值等信息作出补充说明。截至2025年12月31日，海西新药投资资产公允价值合计5.77219亿元，占集团资产总值184.67亿元的31.3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172417268","title":"海西新药7月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1172417268","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172417268?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:31","pubTimestamp":1785745864,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司，于2026年8月3日发布2026年7月股份变动月报表，报告期截至2026年7月31日。公告显示，海西新药在报告期内法定/注册股本总额仍为人民币78,707,270元，与上个月末保持一致。根据公告，截至2026年7月31日，海西新药已发行H股78,707,270股，无新增发行、购回、注销及库存股变动，也无股份期权计划、股权激励方案、可换股票据或其他在本月新增或变动的情况。该月报由公司联席公司秘书张俊环签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653223443","title":"港股午评|恒生指数午盘涨0.03%    芯片股全线走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2653223443","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653223443?lang=zh_cn&edition=full","pubTime":"2026-07-21 12:00","pubTimestamp":1784606453,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.03%，涨7点，报25150点；恒生科技指数涨1.83%。港股午盘成交1576亿港元。消息称智谱建成大型AI数据中心，全部采用国产芯片，半导体全线大涨。智谱涨超25%，落地1GW级国产AI算力数据中心建设，完成对中科加禾收购；MiniMax涨超11%。先导智能涨超7%，拟2亿港元至4亿港元回购H股股份。中国龙工涨超8%，产销规模稳步增长， 上半年纯利最高同比预增27%。恒生创新药指数调整，海西新药跌超6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0052750758.USD","LU0359201612.USD","00981","LU0320764599.SGD","03033","00148","NDGPY","KBDCY","BK1548","513600","688981","LU0384037296.USD","02833","BK1171","07200","688347","LU1282649810.SGD","02837","603986","01888","BK1614","BK1551","SG9999006597.SGD","83115","BK1170","09088","03339","03088","02800","MCHS","BK1163","HK0000500386.USD","LU0708995583.HKD","03419","LU1328277881.USD","07500","LU2039709279.SGD","LU1211504680.USD","FPA","LU0648948544.HKD","WOOD","82800","LU1808992512.USD","BK1607","HK0000252152.HKD","LKHLY","BK1514","BK1526","BK1191","02513","03067","LU0593848301.USD","BK1179","HSTECH","03115","03986","LU1023057109.AUD","BK1181","BK1223","MCHmain","LU2929501877.USD","BK1190","03277","BK1506","07226","09067","300450","HHImain","LU0314109678.HKD","01347","BK1117","SG9999004220.SGD","TCHI","02689","03037","BK1183","03423","LU2187417386.USD","LU1282649067.USD","03032","BK1610","LU0359201885.HKD","LU0488056044.USD","02637","07552","HK0000252160.HKD","HSI","LU0359202008.SGD","06880","09115","LU1813983027.USD","LU1282649141.HKD","00470","SG9999001093.SGD","07300","03417","00100","03858","SG9999002950.SGD","BK1505","SG9999014674.SGD","LU2351347302.SGD","IE0034224299.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100798304","title":"福建海西新药创制股份有限公司（02637）将于8月4日召开2026年第一次临时股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=1100798304","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100798304?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:50","pubTimestamp":1784112633,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司7月15日公告，公司已发出召开2026年第一次临时股东会的通告，会议定于2026年8月4日（星期二）上午十时在中国福建省福州市仓山区建新镇金达路177号B座一楼会议室举行。\\n\\n根据公告，2026年第一次临时股东会的所有决议案将按香港联合交易所有限公司证券上市规则以投票方式表决。记录日期为2026年8月4日；H股股东如欲出席并投票，须在2026年7月29日16时30分前完成股份过户登记。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134835610","title":"海西新药（02637.HK）董事会换血：王忻琨辞任非执董，提名陈廷泽出任执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1134835610","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134835610?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:41","pubTimestamp":1784112075,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司7月15日公告称，公司非执行董事王忻琨因工作调动辞任，其离任自公司股东会选举新董事之日起生效。董事会已接受其辞任，并对其任内贡献表示感谢。与此同时，公司董事会提名陈廷泽为执行董事候选人，并已于2026年7月9日召开的提名委员会会议及7月15日的董事会会议审议通过。若获股东会批准，陈廷泽的任期将自股东会选举通过之日起，至第二届董事会任期届满之日止。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651452821","title":"海西新药(02637.HK)：陈廷泽获提名为执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651452821?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:37","pubTimestamp":1784111829,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651452884","title":"海西新药(02637.HK)建议委任容诚为核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452884","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651452884?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:36","pubTimestamp":1784111760,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150967054","title":"海西新药拟改用中国企会准则并更换核数师　审计费用拟降逾五成","url":"https://stock-news.laohu8.com/highlight/detail?id=1150967054","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150967054?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:35","pubTimestamp":1784111735,"startTime":"0","endTime":"0","summary":"海西新药7月15日公告，公司董事会已通过决议，自2026年6月30日止半年度财务报告起，统一采用中国企业会计准则编制财务报表，并拟在临时股东大会上提请股东批准更换外聘核数师。董事会表示，统一会计准则有助于提升信息披露效率并降低编制成本。董事会已向股东承诺，将适时向股东寄发载有更换核数师详情的通函，并召开临时股东大会审议相关议案。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651336594","title":"港股异动 | 海西新药(02637.HK)涨超4% HXP089用于治疗GBM的新药临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2651336594","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651336594?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:04","pubTimestamp":1784081068,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137318446","title":"海西新药HXP089治疗胶质母细胞瘤IND获批 迈入临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1137318446","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137318446?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:11","pubTimestamp":1784020270,"startTime":"0","endTime":"0","summary":"2026年7月14日，福建海西新药创制股份有限公司发布自愿公告称，公司自主研发的HXP089项目用于治疗胶质母细胞瘤的新药临床试验申请已获国家药品监督管理局药品审评中心批准，获准开展相关临床研究。HXP089是基于公司自主创新小分子药物研发平台MultiSel-Opt开发的新一代化学小分子选择性多靶点创新药，具备通过血脑屏障的能力，拟用于解决胶质母细胞瘤复发后缺乏有效标准治疗药物的临床需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hxpharma.com","stockEarnings":[{"period":"1week","weight":0.0778},{"period":"1month","weight":-0.0224},{"period":"3month","weight":-0.1513},{"period":"6month","weight":0.4765},{"period":"1year","weight":1.3241},{"period":"ytd","weight":0.4765}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":0.0611},{"period":"3month","weight":-0.0279},{"period":"6month","weight":-0.051},{"period":"1year","weight":0.03},{"period":"ytd","weight":0.0009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"福建海西新药创制股份有限公司成立于2012年3月27日。公司是一家处于商业化阶段的制药公司,集研发、生产及销售能力于一体,具备在研创新药的管线。公司在中国最大、增长最快的治疗领域拥有多元化的产品组合及管线。截至最后实际可行日期,公司已商业化的产品组合主要包括用于消化系统疾病、心血管系统疾病、内分泌系统疾病、神经系统疾病及炎症疾病的仿制药。根据灼识咨询的资料,该等治疗领域占2023年中国医药销售总额的25%以上。公司的创新药管线专注于具有各种适应症的在研药物,包括一款潜在属同类首款的在研肿瘤药物、一款潜在用于治疗湿性年龄相关性黄斑变性(wAMD)╱糖尿病性黄斑水肿(DME)╱视网膜静脉阻塞(RVO)的首款口服药物及另外两款处于临床前阶段,用于治疗肿瘤及呼吸系统疾病的创新在研药物。公司所有在研创新药均由内部以专有方式开发及发展。","exchange":"SEHK","name":"海西新药","nameEN":"HAIXI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海西新药,02637,海西新药股票,海西新药股票老虎,海西新药股票老虎国际,海西新药行情,海西新药股票行情,海西新药股价,海西新药股市,海西新药股票价格,海西新药股票交易,海西新药股票购买,海西新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}